Clinical trials: Non-Hodgkin-Lymphoma
COVID-19
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Early Mild Outpatient infusion Therapy with ExoFloTM for COVID-19 (EMOTE COVID-19) To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles…
- Trial name
- NCT05125562
- Testing
- ExoFlo
- Sponsor
- Direct Biologics, LLC
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT01890486
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Wake Forest University Health Sciences
Refractory and Relapsed Primary CNS Lymphoma, PCNSL
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
The purpose of this study was to investigate the maximum tolerated dose and efficacy of Orelabrutinib combined with Thiotepa in refractory and relapsed primary central nervous system lymphoma (PCNSL).
- Conditions
- Refractory and Relapsed Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma
- Trial name
- NCT05021770
- Testing
- Orelabrutinib, Thiotepa
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Huiqiang Huang
Extranodal NK/T-cell Lymphoma
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
The purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.
- Trial name
- NCT04337593
- Testing
- Basiliximab, Pegaspargase
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital
Anaplastic Large-Cell Lymphoma
Denileukine Diftitox for Relapsed ALCL
The purpose of this study is to determine is Denileukin diftitox will be safe, well tolerated and induce a significant overall response alone and in combination with chemotherapy: ifosfamide, carboplatin and etoposide (ICE) and…
- Trial name
- NCT00801918
- Testing
- Denileukin Diftitox, Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Columbia University
B-ALL, B-cell Non Hodgkin Lymphoma
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
- Conditions
- B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
- Trial name
- NCT04088890
- Testing
- Fludarabine, Cyclophosphamide, CD22 CAR
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Matthew Frank
Follicular Lymphoma
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
- Trial name
- NCT06043323
- Testing
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Follicular, Follicular Lymphoma
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma.
- Trial name
- NCT05410418
- Testing
- Mosunetuzumab, Polatuzumab vedotin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene
Extranodal NK/T-cell Lymphoma
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with decitabine in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients
- Trial name
- NCT04279379
- Testing
- Sintilimab, Decitabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Pancreatitis Acute Biliary
Early Endoscopic Ultrasound - Based Sphincterotomy or Conservative Treatment in Severe Biliary Pancreatitis
The primary purpose of this trial is to determine whether an early Early Endoscopic Ultrasound (EUS) immediately followed by an endoscopic sphincterotomy (ES) in case of bile duct stones may improve outcomes in patients with…
- Trial name
- EEPAB2 (NCT00987428)
- Testing
- ultrasonography with or not sphincterotomy, Usual procedure
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
Leukemia, Lymphoma
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
- Trial name
- NCT00077493
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- MedImmune LLC
Peripheral T-Cell Lymphoma
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma.
- Trial name
- NCT01841021
- Testing
- Brentuximab vedotin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoma
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with relapsed…
- Trial name
- NCT00466921
- Testing
- lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Northwestern University
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
This study will examine the safety of clofarabine, TLI and ATG as a reduced conditioning regimen prior to allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00697684
- Testing
- Antithymocyte Globulin, Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Beth Israel Deaconess Medical Center
Diffuse Large B-cell Lymphoma
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the efficacy and safety of Tucidinostat, in…
- Trial name
- DEB (NCT04231448)
- Testing
- R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat
- Where
- 2 sites in China
- Volunteers
- 423 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL)
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the safety and tolerability of TRU-016 in patients with previously treated chronic lymphocytic leukemia, and to obtain an estimate of clinical activity in patients with CLL and…
- Trial name
- NCT00614042
- Testing
- TRU-016 (anti-CD37 protein therapeutic)
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- Aptevo Therapeutics
ALK-activated Tumors
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
The purpose of this study was to estimate the maximum tolerated dose and/or recommended dose for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose…
- Trial name
- NCT01742286
- Testing
- Ceritinib
- Where
- 23 sites in United States, Australia and 8 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.